本帖最后由 老马 于 2012-1-13 21:20 编辑
* u& f' l3 ?! s7 @0 a* o7 |6 H" x! M
爱必妥和阿瓦斯丁的比较) A c7 I/ K8 C6 y
2 C& F* U; j, phttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/+ v5 Q. B1 I' T
0 J% D/ c- Q/ H8 P
+ z) _( ?2 L3 `5 ^. ?0 M4 F, ^- h
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/( v' D, @8 J( _6 \
==================================================
& \2 j4 ?' F8 D0 I% AOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) e" ?+ k G- v) M5 t6 d1 d2 v5 UPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.5 l6 z {0 H/ Z* G t5 @
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.) j# a( s4 u$ T' S& h/ z8 R8 S
|